| 臺大學術典藏 |
2021-01-04T12:12:53Z |
Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies
|
Chen Y.-C.; Yao M.; Huang S.-Y.; Tsay W.; Chen C.-Y.; Tang J.-L.; Hsu C.; Huang T.-C.; Ko B.-S.; HWEI-FANG TIEN; Shen M.-C.; Wang C.-H. |
| 國家衛生研究院 |
2021-01 |
The case for physical activity as an option in the smoking cessation guidelines: Short and long term benefits beyond expectation from regular exercise
|
Wen, C;Gao, WN;Chen, C;Wai, J;Wen, C;Lu, P;Lee, J;Hsu, C |
| 國立成功大學 |
2021 |
Flow-induced Orientations of Fibers and Their Influences on Warpage and Mechanical Property in Injection Fiber Reinforced Plastic (FRP) Parts
|
Huang, C.-T.;Chu, J.-H.;Fu, W.-W.;Hsu, C.;Hwang, S.-J. |
| 國立成功大學 |
2021 |
Novel Algorithm for Improved Protein Classification Using Graph Similarity
|
Chou, H.;Hsu, C.;Hsu, C.;Yao, K.;Wang, H.;Hsieh, S. |
| 國立成功大學 |
2021 |
WikiContradiction: Detecting Self-Contradiction Articles on Wikipedia
|
Hsu, C.;Li, C.-T.;Saez-Trumper, D.;Hsu, Y.-Z. |
| 國立成功大學 |
2021 |
RetaGNN: Relational temporal attentive graph neural networks for holistic sequential recommendation
|
Hsu, C.;Li, C.-T. |
| 臺大學術典藏 |
2020-12-28T08:14:10Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Cheng J.C.-H.;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Yen-Hsuan Ni;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Wang P.-M.; Chao Y.; Chen L.-T.; Hsu C.; Cheng A.-L.; Lin C.-C.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; YEN-HSUAN NI; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2020-12-24T07:08:29Z |
Grape seed proanthocyanidins protect cardiomyocytes from ischemia and reperfusion injury via Akt-NOS signaling
|
Li C.-Q.; Mehendale S.R.; Hsu C.; Dossumbekova A.; Wojcik K.R.; Shao Z.-H.; Qin Y.; Sharp W.W.; WEI-TIEN CHANG; Hamann K.J.; Yuan C.-S.; Vanden Hoek T.L. |
| 臺大學術典藏 |
2020-12-24T06:16:19Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Lee N.-C.; Lai F.; Hsiung H.-C.; Tsai W.-H.; Chiu P.-C.; Chou Y.-Y.; Lee C.-H.; Chen C.-N.; Chang T.-M.; Hsieh W.-S.; Lin S.-P.; Tsai I.-J.; Fan P.-C.; Tsao P.-N.; Chou H.-C.; Chen N.-Q.; Wu E.-T.; Hwu W.-L.; YIN-HSIU CHIEN; Hsu C.; Chen T.-F. |
| 臺大學術典藏 |
2020-12-24T06:16:14Z |
Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes
|
Lee N.-C.; Lai F.; Lin I.-L.; Kuo C.-W.; Hwu W.-L.; YIN-HSIU CHIEN; Hsu C.; Hung M.-Z. |
| 臺大學術典藏 |
2020-12-24T02:03:45Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Tsao P.-N.; HUNG-CHIEH CHOU; Chen T.-F.; Chen N.-Q.; Hsu C.; Chien Y.-H.; Hwu W.-L.; Wu E.-T.; Wu E.-T.;Hwu W.-L.;Chien Y.-H.;Hsu C.;Chen T.-F.;Chen N.-Q.;Hung-Chieh Chou;Tsao P.-N.;Fan P.-C.;Tsai I.-J.;Lin S.-P.;Hsieh W.-S.;Chang T.-M.;Chen C.-N.;Lee C.-H.;Chou Y.-Y.;Chiu P.-C.;Tsai W.-H.;Hsiung H.-C.;Lai F.;Lee N.-C.; Fan P.-C.; Tsai I.-J.; Lin S.-P.; Hsieh W.-S.; Chang T.-M.; Chen C.-N.; Lee C.-H.; Chou Y.-Y.; Chiu P.-C.; Tsai W.-H.; Hsiung H.-C.; Lai F.; Lee N.-C. |
| 臺大學術典藏 |
2020-12-21T08:19:26Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Wu E.-T.;Hwu W.-L.;Chien Y.-H.;Hsu C.;Chen T.-F.;Chen N.-Q.;Chou H.-C.;Tsao P.-N.;Fan P.-C.;I-Jung Tsai;Lin S.-P.;Hsieh W.-S.;Chang T.-M.;Chen C.-N.;Lee C.-H.;Chou Y.-Y.;Chiu P.-C.;Tsai W.-H.;Hsiung H.-C.;Lai F.;Lee N.-C.; Wu E.-T.; Hwu W.-L.; Chien Y.-H.; Hsu C.; Chen T.-F.; Chen N.-Q.; Chou H.-C.; Tsao P.-N.; Fan P.-C.; I-JUNG TSAI; Lin S.-P.; Hsieh W.-S.; Chang T.-M.; Chen C.-N.; Lee C.-H.; Chou Y.-Y.; Chiu P.-C.; Tsai W.-H.; Hsiung H.-C.; Lai F.; Lee N.-C. |
| 臺大學術典藏 |
2020-12-09T01:38:09Z |
Critical Trio Exome Benefits In-Time Decision-Making for Pediatric Patients with Severe Illnesses?
|
Wu E.-T.;Hwu W.-L.;Chien Y.-H.;Hsu C.;Chen T.-F.;Chen N.-Q.;Chou H.-C.;Tsao P.-N.;Fan P.-C.;Tsai I.-J.;Lin S.-P.;Hsieh W.-S.;Chang T.-M.;Chen C.-N.;Lee C.-H.;Chou Y.-Y.;Chiu P.-C.;Tsai W.-H.;Hsiung H.-C.;Lai F.;Ni-Chung Lee; Wu E.-T.; Hwu W.-L.; Chien Y.-H.; Hsu C.; Chen T.-F.; Chen N.-Q.; Chou H.-C.; Tsao P.-N.; Fan P.-C.; Tsai I.-J.; Lin S.-P.; Hsieh W.-S.; Chang T.-M.; Chen C.-N.; Lee C.-H.; Chou Y.-Y.; Chiu P.-C.; Tsai W.-H.; Hsiung H.-C.; Lai F.; NI-CHUNG LEE |
| 臺大學術典藏 |
2020-12-09T01:38:04Z |
Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes
|
Kuo C.-W.;Hwu W.-L.;Chien Y.-H.;Hsu C.;Hung M.-Z.;Lin I.-L.;Lai F.;Ni-Chung Lee; Kuo C.-W.; Hwu W.-L.; Chien Y.-H.; Hsu C.; Hung M.-Z.; Lin I.-L.; Lai F.; NI-CHUNG LEE |
| 臺大學術典藏 |
2020-12-02T02:36:06Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Hsu C.;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Pan-Chyr Yang;Perng R.-P.; Yang C.H.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:35:51Z |
Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13
|
Chie W.-C.;Yang C.-H.;Hsu C.;Pan-Chyr Yang; Chie W.-C.; Yang C.-H.; Hsu C.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:35:46Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
Kuo S.-H.;Yang C.-H.;Yu C.-J.;Hsu C.;Cheng A.-L.;Pan-Chyr Yang; Kuo S.-H.; Yang C.-H.; Yu C.-J.; Hsu C.; Cheng A.-L.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:35:37Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.;Yang C.-H.;Yu C.-J.;Shih J.-Y.;Hsu C.;Pan-Chyr Yang; Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Hsu C.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:34:49Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Yang C.-H.; Shih J.-Y.; Chen K.-C.; Yu C.-J.; Yang T.-Y.; Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; Pan-Chyr Yang; Yang C.-H.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:34:36Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; PAN-CHYR YANG; Yang C.-H. |
| 臺大學術典藏 |
2020-12-02T02:34:30Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; Cheng A.-L.; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; PAN-CHYR YANG; Yang C.-H. |
| 臺大學術典藏 |
2020-11-27T08:14:24Z |
Weekly cisplatin, infusional high-dose 5-fluorouracil and leucovorin for advanced, recurrent and metastatic cervical carcinoma
|
Hsiao S.-M.;Chen C.-A.;Hsu C.;Lin H.-H.;Chang-Yao Hsieh;Wei L.-H.; Hsiao S.-M.; Chen C.-A.; Hsu C.; Lin H.-H.; CHANG-YAO HSIEH; Wei L.-H. |
| 臺大學術典藏 |
2020-11-19T03:43:04Z |
HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity
|
Huang C.-L.; Hsu H.-C.; PO-HUANG LEE; Wang S.-J.; Cheng A.-L.; Hsu C.; Hsu C.;Huang C.-L.;Hsu H.-C.;Po-Huang Lee;Wang S.-J.;Cheng A.-L. |
| 臺大學術典藏 |
2020-11-19T03:42:56Z |
Low-dose thalidomide treatment for advanced hepatocellular carcinoma
|
Hsu C.;Chen C.-N.;Chen L.-T.;Wu C.-Y.;Yang P.-M.;Lai M.-Y.;Po-Huang Lee;Cheng A.-L.; Hsu C.; Chen C.-N.; Chen L.-T.; Wu C.-Y.; Yang P.-M.; Lai M.-Y.; PO-HUANG LEE; Cheng A.-L. |
| 臺大學術典藏 |
2020-11-19T03:19:32Z |
Lc3 over-expression improves survival and attenuates lung injury through increasing autophagosomal clearance in septic mice
|
Lo S.; Yuan S.-S.F.; Hsu C.; Cheng Y.-J.; Chang Y.-F.; Hsueh H.-W.; PO-HUANG LEE; Hsieh Y.-C. |
